Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Gilteritinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 49,603Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 5Xospata

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xospata

    Gilteritinib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Xospata

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Astellas

    Gilteritinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 203

    2019 Revenue in Millions : 107

    Growth (%) : 89

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xospata

    Gilteritinib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Xospata

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Astellas

    Gilteritinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 269

    2020 Revenue in Millions : 201

    Growth (%) : 44

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Xospata

    Gilteritinib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Xospata

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Astellas

    Gilteritinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 358

    2021 Revenue in Millions : 287

    Growth (%) : 25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Xospata

    Gilteritinib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Xospata

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Astellas

    Gilteritinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 348

    2022 Revenue in Millions : 358

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Xospata

    Gilteritinib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Xospata

    Japan
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Astellas

    Gilteritinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 109

    2018 Revenue in Millions : 6

    Growth (%) : 1,850

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF